Skip to content

A Real Life Evaluation of the Performance of a Large Volume Nebulizer

A Real Life Evaluation of the Performance of a Large Volume Nebulizer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00632112
Enrollment
50
Registered
2008-03-10
Start date
2008-03-31
Completion date
Unknown
Last updated
2009-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

large volume nebulizer

Brief summary

Continuous albuterol has become the standard of care for patients in status asthmaticus. We have previously performed an in-vitro study comparing 4 different brands of continuous nebulizers. We now want to compare the in-vitro with the in-vivo performance of the brand we use. we hypothesize that there will be no difference between in-vivo and in-vitro results.

Detailed description

There will be no intervention to the patients. Nebulizers will be used as per current policies and procedures. They will only be marked on the outside at the water level every 2 hours for the first 6 hours. Once ready to be discarded will be collected for laboratory testing Once in the laboratory, nebulizers will be weight on a precision scale without liquid, then they will be filled with normal saline to the first mark (6th hour) and re-weight. The nebulizers will be filled to next mark and re-weight until 200 mls. of total volume are achieved. Solution output will be calculated as the weight difference between the 2 hour periods.

Interventions

None listed

Sponsors

S&T Medical Technologies, Inc.
CollaboratorINDUSTRY
Arkansas Children's Hospital Research Institute
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients admitted to Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.

Exclusion criteria

* Patients requiring invasive or non-invasive ventilation.

Design outcomes

Primary

MeasureTime frame
Nebulizer solution outputevery 2 hours for first 6 hours

Countries

United States

Contacts

Primary ContactAriel Berlinski, M.D.
berlinskiariel@uams.edu501-364-1006

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026